Contributions
Abstract: EP1726
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: Ocrelizumab (OCR) is the first disease-modifying therapy (DMT) to treat relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis and is approved in the United States and European Union. Real-world evidence on OCR treatment is limited in the literature.
Objective: To describe demographics, clinical characteristics and treatment patterns of patients with MS who initiated OCR treatment in the first year of approval.
Methods: This study used data from the Adelphi Multiple Sclerosis Disease Specific Programme (DSP), a cross-sectional survey collecting data from neurologists and patients with MS with a broad geographical spread across the United States between March and May 2018. Data were analyzed from a population of patients currently receiving OCR, with a target of 300 OCR patients by late 2018. Demographic and clinical characteristics, including Expanded Disability Status Scale (EDSS) and DMT history, were reported by the physician.
Results: Among the 75 patients currently using OCR, 36% had relapsing-remitting MS (RRMS) and 64% had PPMS. The mean (SD) age was 46.8 (9.0) years, and the mean (SD) time since MS diagnosis was 5.6 (4.9) years. At the time of switching to OCR, the majority of patients had moderate (55%) to severe (12%) compared with low (28%) disease activity, and a mean (SD) EDSS score of 4.1 (1.7) points. No previous DMT use was reported in 23% of OCR patients. Among patients who switched to OCR, 57% switched from platform therapies (interferons or glatiramer acetate), 31% from orals (teriflunomide, fingolimod, dimethyl fumarate or cladribine) and 11% from another infusion product (daclizumab, mitoxantrone, natalizumab or alemtuzumab). Reasons (multiple options) for switching from previous DMT to OCR included patient compliance (32%), efficacy (63%), side effects/safety (43%) and reasons relating to insurance (9%).
Conclusions: To our knowledge, this is one of the first real-world studies describing the demographic, disease and treatment characteristics of real-world ocrelizumab users. Data collection is ongoing, and we expect to present results from the complete sample at the time of the 2018 ECTRIMS meeting.
Disclosure: Sponsored by Genentech, Inc. N.J. Engmann is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; E. Jones is an employee of Adelphi Real World and was funded by Genentech, Inc. to complete this analysis; J. Husbands is an employee of Adelphi Real World and was funded by Genentech, Inc. to complete this analysis; W.S.Yeh is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; J. Whiteley is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; L. Julian is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd.
Abstract: EP1726
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: Ocrelizumab (OCR) is the first disease-modifying therapy (DMT) to treat relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis and is approved in the United States and European Union. Real-world evidence on OCR treatment is limited in the literature.
Objective: To describe demographics, clinical characteristics and treatment patterns of patients with MS who initiated OCR treatment in the first year of approval.
Methods: This study used data from the Adelphi Multiple Sclerosis Disease Specific Programme (DSP), a cross-sectional survey collecting data from neurologists and patients with MS with a broad geographical spread across the United States between March and May 2018. Data were analyzed from a population of patients currently receiving OCR, with a target of 300 OCR patients by late 2018. Demographic and clinical characteristics, including Expanded Disability Status Scale (EDSS) and DMT history, were reported by the physician.
Results: Among the 75 patients currently using OCR, 36% had relapsing-remitting MS (RRMS) and 64% had PPMS. The mean (SD) age was 46.8 (9.0) years, and the mean (SD) time since MS diagnosis was 5.6 (4.9) years. At the time of switching to OCR, the majority of patients had moderate (55%) to severe (12%) compared with low (28%) disease activity, and a mean (SD) EDSS score of 4.1 (1.7) points. No previous DMT use was reported in 23% of OCR patients. Among patients who switched to OCR, 57% switched from platform therapies (interferons or glatiramer acetate), 31% from orals (teriflunomide, fingolimod, dimethyl fumarate or cladribine) and 11% from another infusion product (daclizumab, mitoxantrone, natalizumab or alemtuzumab). Reasons (multiple options) for switching from previous DMT to OCR included patient compliance (32%), efficacy (63%), side effects/safety (43%) and reasons relating to insurance (9%).
Conclusions: To our knowledge, this is one of the first real-world studies describing the demographic, disease and treatment characteristics of real-world ocrelizumab users. Data collection is ongoing, and we expect to present results from the complete sample at the time of the 2018 ECTRIMS meeting.
Disclosure: Sponsored by Genentech, Inc. N.J. Engmann is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; E. Jones is an employee of Adelphi Real World and was funded by Genentech, Inc. to complete this analysis; J. Husbands is an employee of Adelphi Real World and was funded by Genentech, Inc. to complete this analysis; W.S.Yeh is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; J. Whiteley is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd; L. Julian is an employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd.